Annual accounts & ratios
Source: NBB · 2025How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil–Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Fiscal year | 2025 |
|---|---|
| Revenue | — |
| EBITDA | €-84.90M |
| Net profit | €-121.09M |
| Cash flow | €-121.09M |
| Staff costs | €1.50M |
| Income taxes | €2k |
| Dividends | — |
| Total assets | €118.59M |
| Equity | €37.95M |
| Debt | €2.55M |
| of which ≤ 1y | €2.54M |
| of which > 1y | — |
| Working capital | €116.05M |
| Employees (FTE) | 4.1 |
| 2025 | |
|---|---|
| Current ratio | 46.78 |
| Quick ratio | 46.78 |
| Working capital ratio | 97.9% |
| Solvency | 32.0% |
| Debt / equity | 0.07 |
| Long-term debt ratio | — |
| Interest coverage | -1916.65 |
| Gross margin | — |
| Net margin | — |
| ROA | -102.1% |
| ROE | -319.1% |
| EBITDA margin | — |
| Days sales outstanding | — |
| Days payable outstanding | 136d |
| Inventory turnover | — |
| Days inventory (DSI) | — |
| Line item | Code | 2025 |
|---|---|---|
| Balance sheet — Assets | ||
| TOTAL ASSETS | 20/58 | €118.59M |
| Fixed assets | 21/28 | €9k |
| Tangible fixed assets | 22/27 | €5k |
| Financial fixed assets | 28 | €4k |
| Current assets | 29/58 | €118.59M |
| Amounts receivable within one year | 40/41 | €86.88M |
| Investments | 50/53 | €2k |
| Cash & bank | 54/58 | €31.45M |
| Balance sheet — Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €118.59M |
| Equity | 10/15 | €37.95M |
| Contributions / capital | 10/11 | €171.67M |
| Accumulated profits (losses) | 14 | €-133.73M |
| Provisions & deferred taxes | 16 | €78.10M |
| Amounts payable | 17/49 | €2.55M |
| Amounts payable within one year | 42/48 | €2.54M |
| Trade debts payable within one year | 44 | €2.46M |
| Income statement | ||
| Gross operating margin | 9900 | €-5.30M |
| Operating result | 9901 | €-84.91M |
| Financial income | 75 | €88k |
| Financial charges | 65 | €44k |
| Result before taxes | 9903 | €-121.09M |
| Income taxes | 67/77 | €2k |
| Net result for the period | 9904 | €-121.09M |
| Result to be appropriated | 9905 | €-121.09M |
Health barometer
FY 2025 · computedUnlock the full score breakdown, per-year score history and the indicative credit limit from Starter.
See plans →